Tanja Obradovic: Interesting updates will be coming on ASCO 2024
Tanja Obradovic, Vice President of Oncology Scientific Affairs at
“ASCO 2024 is almost here with abstract titles out few days ago. Interesting updates will be coming across numerous cancers in many presentations. Within Plenary Sessions, chosen for discussion are LAURA and ADRIATIC trials in NSCLC and SCLC, respectively. Also, highly anticipated NADINA trial that Nature Medicine’s annual feature named as one of trials that will shape medicine in 2024.
The NADINA clinical trial is the first one to compare neoadjuvant vs adjuvant immunotherapy treatment in macroscopic stage III melanoma preventing recurrence. Results can change need for current adjuvant standard with monotherapy. Also, possibly open deeper discussion beyond melanoma on neoadjuvant vs adjuvant contribution to efficacy in other tumor types. After full text publication goes live on 23rd of May we’ll know much more.
Link to ASCO program.
Link to Nature Medicine publication.”
Source: Tanja Obradovic/LinkedIn